Champlain Investment Partners’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-2,687,972
Closed -$95.3M 125
2024
Q1
$95.3M Buy
2,687,972
+252,015
+10% +$10.1M 0.55% 74
2023
Q4
$106M Sell
2,435,957
-2,872
-0.1% -$113K 0.63% 66
2023
Q3
$93.1M Sell
2,438,829
-1,462,894
-37% -$61.5M 0.6% 68
2023
Q2
$160M Sell
3,901,723
-1,269,936
-25% -$61.1M 0.99% 36
2023
Q1
$297M Sell
5,171,659
-87,865
-2% -$4.95M 1.87% 7
2022
Q4
$295M Sell
5,259,524
-100,031
-2% -$5.09M 1.89% 5
2022
Q3
$227M Sell
5,359,555
-93,260
-2% -$4.78M 1.55% 10
2022
Q2
$295M Sell
5,452,815
-132,915
-2% -$7.98M 1.9% 6
2022
Q1
$359M Sell
5,585,730
-109,107
-2% -$7.18M 1.86% 5
2021
Q4
$381M Sell
5,694,837
-32,400
-0.6% -$2.19M 1.73% 6
2021
Q3
$392M Sell
5,727,237
-782,793
-12% -$55.3M 1.88% 3
2021
Q2
$444M Sell
6,510,030
-19,145
-0.3% -$1.35M 2.11% 2
2021
Q1
$451M Buy
6,529,175
+70,710
+1% +$4.79M 2.35% 1
2020
Q4
$419M Buy
6,458,465
+187,445
+3% +$10.1M 2.41% 2
2020
Q3
$296M Buy
6,271,020
+62,910
+1% +$2.99M 2.01% 5
2020
Q2
$292M Buy
6,208,110
+8,890
+0.1% +$437K 2.09% 3
2020
Q1
$277M Buy
6,199,220
+132,560
+2% +$6.96M 2.49% 1
2019
Q4
$354M Buy
6,066,660
+387,900
+7% +$23.1M 2.58% 1
2019
Q3
$341M Sell
5,678,760
-81,470
-1% -$4.85M 2.81% 1
2019
Q2
$322M Buy
5,760,230
+286,410
+5% +$14.7M 2.7% 1
2019
Q1
$305M Buy
5,473,820
+77,845
+1% +$3.96M 2.66% 1
2018
Q4
$243M Buy
5,395,975
+53,390
+1% +$2.93M 2.47% 1
2018
Q3
$352M Buy
5,342,585
+211,115
+4% +$13.1M 3.12% 1
2018
Q2
$331M Buy
5,131,470
+133,875
+3% +$8.29M 3.2% 1
2018
Q1
$277M Buy
4,997,595
+351,520
+8% +$18.4M 2.99% 1
2017
Q4
$222M Buy
4,646,075
+110,355
+2% +$5.4M 2.52% 3
2017
Q3
$229M Buy
4,535,720
+88,031
+2% +$4.52M 2.7% 1
2017
Q2
$242M Buy
4,447,689
+8,929
+0.2% +$426K 2.96% 1
2017
Q1
$187M Buy
4,438,760
+497,530
+13% +$21.3M 2.46% 3
2016
Q4
$169M Buy
3,941,230
+686,032
+21% +$27.9M 2.34% 5
2016
Q3
$134M Sell
3,255,198
-31,452
-1% -$1.32M 2.04% 6
2016
Q2
$131M Buy
3,286,650
+287,850
+10% +$10.4M 2.26% 5
2016
Q1
$101M Buy
2,998,800
+35,050
+1% +$1.09M 1.83% 9
2015
Q4
$100M Sell
2,963,750
-94,730
-3% -$2.96M 1.72% 9
2015
Q3
$91.1M Sell
3,058,480
-423,302
-12% -$13.2M 1.59% 10
2015
Q2
$95.9M Sell
3,481,782
-28,355
-0.8% -$756K 1.51% 11
2015
Q1
$88.5M Sell
3,510,137
-25,076
-0.7% -$593K 1.51% 15
2014
Q4
$78.4M Buy
3,535,213
+200,806
+6% +$4.07M 1.25% 23
2014
Q3
$67.7M Sell
3,334,407
-71,681
-2% -$1.43M 1.17% 19
2014
Q2
$65.5M Buy
3,406,088
+39,217
+1% +$731K 1.07% 22
2014
Q1
$63.3M Sell
3,366,871
-41,994
-1% -$810K 1.09% 23
2013
Q4
$66.5M Sell
3,408,865
-118,519
-3% -$2.17M 1.17% 20
2013
Q3
$58M Buy
3,527,384
+8,954
+0.3% +$144K 1.1% 29
2013
Q2
$52.7M Buy
+3,518,430
New +$51.6M 1.06% 28

Other funds holding IART

Champlain Investment Partners's IART Position: Q2 2024 in Review

Champlain Investment Partners sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 2,687,972 shares — an estimated $95.3M sold.

Champlain Investment Partners first reported a position in IART in Q2 2013 and held it in 44 quarters. The position peaked at $451M in Q1 2021. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.

  • Champlain Investment Partners reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Champlain Investment Partners sold 2,687,972 Integra LifeSciences shares in Q2 2024, an estimated $95.3M.
  • Champlain Investment Partners first reported a position in Integra LifeSciences in Q2 2013 and held it in 44 quarters.
  • Champlain Investment Partners's Integra LifeSciences position peaked at $451M in Q1 2021.
  • 238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.

Based on Champlain Investment Partners's 13F filing for Q2 2024, filed 14 Aug 2024.